Recent studies have shown that the intranasal administration of TRPA1 agonists stimulates CGRP release and increases meningeal blood flow, suggesting that these events may contribute to the onset of headaches triggered by environmental irritants[12,13]. The gene discussed is TRPA1; the disease is Headache.